TransDigm (TDG) director granted 518 stock options at $1,291.97
TransDigm Group (TDG) — Form 4: Director Gary McCullough reported a grant of stock options on 11/04/2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
TransDigm Group (TDG) — Form 4: Director Gary McCullough reported a grant of stock options on 11/04/2025. The award covers 518 options to purchase common stock at an exercise price of $1,291.97 per share, expiring on 11/04/2035. The filing lists 518 derivative securities beneficially owned following the transaction, held direct.
Per the footnote, the options vest 20% per year over five years beginning September 30, 2026, and are subject to annual operating performance targets.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 518 | $0.00 | $0.00 |
Footnotes (1)
- F1. These options are exercisable at 20% per year over five years beginning September 30, 2026 subject to the achievement of annual operating performance targets in each year.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did TransDigm (TDG) disclose in this Form 4?
What is the vesting schedule for the TDG options?
What is the expiration date of the options reported by TDG?
How many derivative securities are held after the transaction?
What is the ownership form of the reported TDG options?
Who is the reporting person in this TDG Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.